Skip to main content

Table 1 STOP-CKD study objectives

From: Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial

Pilot study

To determine the recruitment rate and feasibility of the study

Quantitative arm

Primary

To determine the effect of spironolactone on arterial stiffness in patients with stage 3 CKD

Secondary

To determine the safety of spironolactone in stage 3 CKD in a primary care setting, in regards to the incidence of hyperkalaemia, worsened renal function and other adverse events

To assess the effect of spironolactone on blood pressure and albuminuria in stage 3 CKD

To assess the effect of spironolactone on pulse wave characteristics

Potassium substudy

To examine whether the different methods of serum processing affect the rate of hyperkalaemia seen in primary care

Qualitative arm

To examine patients’ and healthcare professionals’ attitudes towards CKD and research in CKD in the community setting

Explore patients’ and healthcare professionals’ attitudes towards the use of spironolactone in CKD in a community setting and potential barriers to its use

Back to article page

Trials

ISSN: 1745-6215